ie-net ingenieursvereniging vzw is hét contactpunt tussen ingenieurs, bedrijven, overheids- en opleidingsinstellingen en wil door haar activiteiten o.a. de sleutelrol van ingenieurs in onze moderne economie en maatschappij versterken. Vanuit deze missie streeft de Expertgroep “Chemische en Biochemische Techniek” van ie-net naar een betere maatschappelijke inburgering van technologische kennis. Daarom wordt een nieuwe, tweejaarlijkse lezingencyclus “eFFECT (events in Flanders Focusing on Engineering and Chemical Technology)” georganiseerd. Deze cyclus omvat een aantal lezingen rondom een technologisch en maatschappelijk relevant hoofdthema.
Voor de eerste cyclus in het voorjaar van 2017 werd gekozen voor “Chemische Technologie & gezondheid” als hoofdthema. Sprekers afkomstig uit zowel de industrie als de academische wereld zullen een actuele stand van zaken geven over een breed scala van gerelateerde onderwerpen.
De lezingencyclus is opgebouwd uit drie verschillende sessies (met telkens drie lezingen per sessie) die elk plaats zullen hebben bij een andere Vlaamse universiteit, te weten KU Leuven, UGent en UAntwerpen. Met deze cyclus willen we een breed publiek aanspreken: niet enkel ingenieurs, maar ook (master- en doctoraats)studenten en het brede publiek zijn van harte welkom!
Ontvangst en registratie deelnemers
Prof. Fardim (KUL)
Chemical Engineering for Healthcare
Prof. Perrut (Atelier FSC)
Supercritical Fluid Applications in Health Sciences
A. Privat Maldonado (UA)
Plasma Chemistry in Healthcare
Chemical Engineering for Healthcare
Department of Chemical Engineering, KU Leuven, Belgium
Chemical engineering is a result of needs to design processes and equipment for the chemical industry. Chemical engineering has evolved to product design in different industrial sectors including consumer products, pharmaceuticals, materials, platform chemicals and energy. Currently chemical engineering is expanding to new fields to meet emerging challenges in our society such as climate change, ageing and healthcare. In Europe, we have rising and potentially unsustainable healthcare costs due to increasing societal demands, ageing population requiring more diversified care and increasing prevalence of chronic diseases. Moreover, we are facing a decrease of research and innovation productivity in the European healthcare industry. These challenges bring also excellent opportunities. Chemical engineering for healthcare is a new multidisciplinary field combining chemical engineering, material sciences and life sciences. It is a holistic field covering functional therapeutics, functional prevention, personal care and sustainable processes. Functional therapeutics involves the creation of new biomaterials for tissue engineering, implants, targeted drug delivery, diagnostics and also processes in drug discovery, purification and crystallisation. Functional prevention involves the holistic of product design and formulation without health threatening additives or components for example in food and performance materials used in construction and automobiles. Personal care focuses on design of sustainable products such as cosmetics, personal hygiene and cleaning products. Sustainable processes involve the development of new processes combining chemical and biochemical processes using bio-based and renewable raw materials. Chemical engineers can contribute actively to create and to improve life quality of our society by incorporating concepts of healthcare in product and process design and enhancing the competitiveness of Europe in advanced healthcare solutions. Education in this field is a pioneering initiative and can inspire a multitude of opportunities in science and business.
Pedro FARDIM - BIOGRAPHY
Professor Pedro Fardim obtained his Ph.D. in Chemistry in 1999 at Lab. of Biological Chemistry, Campinas State University (UNICAMP) in Brazil. In 2000 he became associated with the Process Chemistry Centre at the Åbo Akademi University (ÅA) in Finland as post-doctoral researcher and in 2004 he obtained his Habilitation in Chemical Engineering and was appointed Adjunct Professor. In August 2005 he was appointed as full Professor in Biomass Chemical Engineering at the Laboratory of Fibre and Cellulose Technology at ÅA. During 1992 to 1999 he has worked as supervisor in a R&D&I laboratory of a top level biomaterials company in Brazil. His company driven project activities covered the whole field from plant genetics to biomaterials. Pedro Fardim main research interest lie within the area of health care, polysaccharides, biofibres, bioshapes, hybrid materials, topochemistry and process chemistry, nanoscience and spectroscopy and he has published more than 100 papers in scientific journals and books, and given more than 60 invited talks at conferences and research institutions. Pedro Fardim is fellow of the Royal Society of Chemistry and International Academy of Wood Science, associated editor of Journal of Polymer Engineering, editorial board member of Carbohydrate Polymers, Cellulose Chemistry and Technology, Journal of Renewable Materials, Journal of Nanoscience with Advanced Technology, International Journal of Lignocellulosic Products, ARKIVOC and Helyion. He is also member of the management committees of COST actions MP1202 (Hybrid materials) and FP1205 (Regenerated cellulose), leader of WG for devices and applications (MP1202) and the vice-president of education for the European Polysaccharide Network of Excellence (EPNOE), a non-profit organization dedicated to promote the investigation and innovative utilization of polysaccharides. He created the ÅA Expert program to offer advanced education to industry interested in biobased materials and the Finnish-Brazilian Network of Excellence in Biomass and Renewable Energy (NOBRE) to build bridges between Finnish and Brazilian partners. Since October 2015 he is Professor in Chemical Engineering for Health Care at the Department of Chemical Engineering at University of Leuven (KU Leuven) in Belgium.
Supercritical Fluid applications in Health Sciences
Atelier Fluides Supercritiques Nyons (France)
Supercritical fluid technology is no longer a “curiosity” but is reaching its industrial age, the more because of the growing demand for processes and products compatible with a sustainable development saving both energy and raw materials, and limiting any type of long-life residues while delivering “safe” products.
In this lecture, I will briefly present the basis of this technology and its advantages and limitations. Then, I will focus my talk on applications in the field of health sciences:
- Extraction and purification of high-quality active ingredients for nutraceuticals and pharmaceuticals;
- Purification and morphology improvement of excipients;
- Sterilisation of injectable APIs;
- Formulation of APIs for various delivery modes: Micro-particles for inhalation, microencapsulation for sustained-release, bioavailability of poorly-soluble molecules, tablet coating;
- Impregnation of medical systems like ocular lens and implants, catheters,…;
- Manufacture of bio-resorbable hemostatic plasters by partial oxidation of cellulose;
- Preparation of bone grafts by human bone delipidation and sterilisation, and elaboration of bone substitutes.
Michel PERRUT- BIOGRAPHY
University cursus :
- Engineering graduation Ecole Polytechnique (PARIS) 1968
- Ph.D. Chemical Engineering in NANCY 1972
- Research group leader at ELF-AQUITAINE Research Center on oil refining (Lyon) 1972-1979
- Professor of Chemical Engineering Institut National Polytechnique de Lorraine (ENSIC-Nancy) 1979-1990
- Founder of SEPAREX in 1985, PHILOR in 199, HITEX in 1997 and Atelier Fluides Supercritiques in 2010
- President & CEO of SEPAREX 1991-2000 and 2004-2012
- Chief Technology Officer, LAVIPHARM (East Windsor, New-Jersey, USA) 2000-2003
- Scientific and business consultant of FeyeCon Group (2012-2013) and SEPAREX (2014-2016)
- General Manager of PHILOR Sarl since 1997
- President of Atelier Fluides Supercritiques SAS since 2010 www.atelier-fsc.com
Founder and Treasurer of the International Society for the Advancement of Supercritical Fluids www.isasf.net
Chairman of several congresses on Supercritical fluids and Chromatography processes
Leader of several European R&D program consortiums
Consultant of several companies (Elf-Aquitaine) and institutions (Institut Français du Pétrole, public agencies):1979-2000
Author (or co-author) of around 180 publications or communications and 40 patents.
Plasma chemistry in healthcare
Angela Privat Maldonado
Plasma in healthcare: the intersection between physics, chemistry, biology, engineering, and medicine
Since Irvin Langmuir first used the term “plasma” to describe (partially) ionized gases, the number of plasma applications continues to expand. Plasma is made up of radicals, ions, excited neutrals, photons and electrons. This cocktail of reactive species provides plasma with the possibility to perform chemistry that is impossible in traditional chemistry. This unique feature lead to applications in micro-electronics, food industry, aerospace industry, energy and environment, and material science. More recently, also the medical world gained interest in plasma due to the breakthrough that permits production of plasma below 40 °C. This evolution permitted the treatment of biological, thermolabile objects, leading to the development of wound healing applications, and using plasma for cancer therapy.
At this point, using plasmas to treat chronic and infected wounds is brought into clinical practice because the results are superior compared to traditional treatments, a result of the exotic chemical composition of plasma. Furthermore, extensive research is performed right now to steer plasma cancer treatment in the same direction. This lecture intends to give an overview of the evolution of plasma applications in healthcare, and why plasmas are particularly interesting to add to the existing treatment options.
Angela PRIVAT MALDONADO - BIOGRAPHY
Angela Privat Maldonado studied biology at Cayetano Heredia Peruvian University in Lima, Peru. Her research on tropical infectious diseases in Peru motivated her to search for novel therapies that could be moved from the researchers' bench to the patient’s bedside. She did an interdisciplinary PhD at the University of York, UK using low temperature plasmas (LTPs) for bacteria inactivation. Currently, she is a post-doctoral researcher in the PLASMANT group at the University of Antwerp investigating the response of tumour cells to LTPs. Her research interests involve LTPs, metastatic cancer and translational science.